Libtayo first immunotherapy to win EC approval for advanced BCC

25 June 2021
sanofi_big

The European Commission (EC) has approved Sanofi (Euronext: SAN) and Regeneron’s (NASDAQ: REGN) PD-1 inhibitor Libtayo (cemiplimab) to treat locally advanced or metastatic basal cell carcinoma (BCC) patients who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).

BCC is the most common type of skin cancer worldwide, representing up to 80% of non-melanoma skin cancers, and incidence is increasing across many European countries.

"Libtayo has redefined the standard of care for advanced CSCC and has the potential to do the same in advanced BCC"While the large majority of BCC cases are caught early and easily cured with surgery or radiation, a small proportion can develop into advanced BCC and penetrate deeper into surrounding tissues (locally advanced) or spread to other parts of the body (metastatic), becoming more difficult to treat.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology